# Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

> **NCT01516346** · PHASE2 · COMPLETED · sponsor: **Corporal Michael J. Crescenz VA Medical Center** · enrollment: 44 (actual)

## Conditions studied

- Heart Failure
- Congestive Heart Failure

## Interventions

- **DRUG:** Isosorbide Dinitrate
- **DRUG:** Isosorbide Dinitrate + Hydralazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01516346
- **Lead sponsor:** Corporal Michael J. Crescenz VA Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2016-02-05
- **Final completion:** 2017-08-18
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-06-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516346, "Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01516346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*